Acurx Pharmaceuticals Stock (NASDAQ: ACXP)

Acurx Pharmaceuticals (NASDAQ:ACXP) Stock, Quote.Headers.trade-ideas

Acurx Pharmaceuticals

Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.

Dominos pizza

News

Intraday Update

Markets

Movers

Trading Ideas

ACXP

ADTX

AGEN

APVO

AREB

BYND

CETU

CHUY

COMM

CSIQ

CURV

FDMT

FTEL

INFY

JCSE

KOPN

LCFY

LESL

LGVN

LPSN

NKGN

ONCO

SDST

SILO

SPWR

TCBI

TCRT

VIRT

ZIMV

Why Domino&#39;s Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Penny Stocks

Small Cap

Pre-Market Outlook

AILE

BRSH

FLGC

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

NRXP

PLAG

RETO

SELX

SMFL

SNGX

SPEC

TANH

TENX

TIRX

TPET

ZAPP

Shares of  Alcoa Corporation (NYSE: AA) rose sharply in today’s pre-market trading after the company reported better-than-expected sales for its first quarter.

Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

ABAT

ACIC

ADAG

ALEC

BFRG

CART

CGTX

COMP

CRGE

CVGW

DOCN

DWAC

ESPR

HOVR

Kintara Therapeutics, Inc. - Common Stock

KTRA

LQDA

MARK

Airspan Networks Holdings Inc. Common Stock

MIMO

MNSO

NUKK

PHUN

PRGS

PRQR

RNAZ

ROMA

RVSN

SAVE

SBGI

SEDG

SHOT

TELL

TREE

Shares of Airspan Networks Holdings Inc. (NASDAQ: MIMO) shares rose sharply during Wednesday’s session after the company announced a partnership with GCT Semiconductor to develop an RF module.

Airspan Networks Holdings shares surged 381% to $0.3699 on Wednesday.

Why Airspan Networks Shares Are Trading Higher By Over 380%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals Inc

JP Morgan analyst John Royall downgrades Murphy USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUSA#NYSE">MUSA</a>) from Neutral to Underweight and raises the price target from $415 to $435.

Downgrades

Price Target

Analyst Ratings

MUSA

JP Morgan Downgrades Murphy USA to Underweight, Raises Price Target to $435

Leerink Partners analyst Michael Cherny maintains Progyny (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGNY#NASDAQ">PGNY</a>) with a Market Perform and lowers the price target from $25 to $21.

PGNY

Leerink Partners Maintains Market Perform on Progyny, Lowers Price Target to $21

<a href="https://www.astrazeneca-us.com/media/press-releases/2024/astrazeneca-announces-start-of-recruitment-in-2-new-phase-iii-trials-evaluating-saphnelo-in-cle-and-in-iim.html" title="https://www.astrazeneca-us.com/media/press-releases/2024/astrazeneca-announces-start-of-recruitment-in-2-new-phase-iii-trials-evaluating-saphnelo-in-cle-and-in-iim.html">https://www.astrazeneca-us.com/media/press-releases/2024/astrazeneca-announces-start-of-recruitment-in-2-new-phase-iii-trials-evaluating-saphnelo-in-cle-and-in-iim.html</a>

Biotech

General

AstraZeneca Initiates Recruitment For Two New Phase III Trials Investigating SAPHNELO In Cutaneous Lupus Erythematosus (LAVENDER) And Idiopathic Inflammatory Myopathies (JASMINE)

The New Rack-Scale Ready FlexTwin&#x2122; Systems Deliver Unprecedented Compute-Density in a Multi-Node Form Factor, with DLC dual CPUs up to 500W Each per Node, Front Node Access and Optimized Networking&nbsp;
SAN JOSE, Calif., Sept. 19, 2024 /PRNewswire/ -- Supermicro, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) a Total IT Solution Provider for AI/ML, HPC, Cloud, Storage, and 5G/Edge is announcing the all-new FlexTwin family of systems which has been designed to address the needs of scientists, researchers, governments, and enterprises undertaking the world's most complex and demanding computing tasks. Featuring flexible support for the latest CPU, memory, storage, power and cooling technologies, FlexTwin is purpose-built to support demanding HPC workloads including financial services, scientific research, and complex modeling. These systems are cost-optimized for performance per dollar and can be customized to suit specific HPC applications and customer requirements thanks to Supermicro's modular Building Block Solutions&#xAE; design.

SMCI

Supermicro Announces The All-New FlexTwin Family Of Systems Which Has Been Designed To Address The Needs Of Scientists, Researchers, Governments, And Enterprises Undertaking The World's Most Complex And Demanding Computing Tasks

JP Morgan analyst Jessica Fye downgrades Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) from Overweight to Neutral and raises the price target from $52 to $57.

HALO

JP Morgan Downgrades Halozyme Therapeutics to Neutral, Raises Price Target to $57

RBC Capital analyst Gregory Renza reiterates Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Outperform and maintains $55 price target.

Reiteration

AGIO

RBC Capital Reiterates Outperform on Agios Pharmaceuticals, Maintains $55 Price Target

Semiconductor stocks especially the ones linked to artificial intelligence technology led by Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>), Advanced Micro Devices, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>), Super Micro Computer, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) picked up after the U.S. Federal Reserve cut <a target="_blank" href="https://in.benzinga.com/markets/equities/24/09/40932103/it-stocks-on-the-rise-after-u-s-fed-cuts-interest-rate" rel="noreferrer noopener">benchmark interest rate</a> to spur growth.
The U.S. Federal Reserve decided to cut its benchmark interest rate by 50 basis points in a first since 2020, setting the interest rate at 4.75% and 5%. The cut is expected to boost discretionary spending by the companies.
The rate cut will be a welcome move, as semiconductor companies have invested heavily in Big Tech (including Microsoft Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/msft#NASDAQ">MSFT</a>), Amazon.Com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and Google parent Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)) spending on their artificial intelligence ambitions, which entail substantial capital expenditures.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/09/40926422/super-micro-poised-for-expansion-as-gross-margin-concerns-ease-internal-control-risks-priced-in-anal" rel="noreferrer noopener">Super Micro Poised for Expansion as Gross Margin Concerns Ease, Internal Control Risks Priced In: Analyst</a>
The semiconductor companies are also under pressure due to the U.S. sanctions on China, a crucial market. Therefore, U.S. investors and the semiconductor chiefs closely watch the agenda of the next President, expecting a softer stance on China.
As per <a target="_blank" href="https://www.benzinga.com/news/24/09/40790177/harris-vs-trump-us-stocks-face-growing-risks-amid-economic-uncertainty-and-upcoming-presidential-ele" rel="noreferrer noopener">a CNBC survey</a>, Republican candidate Donald Trump appeared to be an investor favorite as the S&amp;P 500 and Nasdaq noted significant upside during Trump's tenure as President.
However, the current Biden administration has started doling out semiconductor grants to the companies to consolidate its position.
Contract chipmaker Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>), a crucial AI chip supplier for U.S. semiconductor companies, remains hugely invested in <a target="_blank" href="https://www.benzinga.com/news/24/09/40928754/what-has-taiwan-semiconductor-stock-done-since-nvidia-earnings" rel="noreferrer noopener">its Arizona fab construction</a> to produce AI chips after bagging U.S. chip subsidies. It recently secured two smartphone chip deals from Google and Apple.
Price Actions: NVDA stock is up 3.16% at $116.95 premarket at last check Thursday. AMD is up 3.74% at $153.84, AVGO is up 3.45% at $167.25, SMCI is up 3.00% at $450.00, TSM is up 2.80% at $171.97, INTC is up 2.31% at $21.25, ARM is up 3.78% at $143.59.
Photo via Shutterstock

Government

Regulations

Tech

AMZN

AVGO

GOOG

GOOGL

INTC

MSFT

NVDA

What's Going On With AI Related Stocks Nvidia, AMD, Broadcom And Super Micro On Thursday?

Zeta Marketing Platform brings next-generation AI capabilities to enhance Yahoo marketing and amplify precision and reach for brands
Zeta Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>), the AI-powered marketing Cloud, and Yahoo, a global media and tech company that serves as the trusted guide to the internet for hundreds of millions of people globally, today announced plans to migrate Yahoo's email marketing to the Zeta Marketing Platform (ZMP). Additionally, Zeta's Data Cloud is now interoperable with Yahoo ConnectID, enabling Yahoo DSP users to seamlessly activate audiences to deliver higher returns on investment.

ZETA

Zeta Global And Yahoo Announces Plans To Migrate Yahoo's Email Marketing To The Zeta Marketing Platform, Zeta's Data Cloud Is Now Interoperable With Yahoo ConnectID, Enabling Yahoo DSP Users To Seamlessly Activate Audiences To Deliver Higher Returns On Investment

Management

GRYP

Gryphon Digital Mining Terminates Robby Chang As CEO And President, Appoints Steve Gutterman As New CEO Effective September 17, 2024

JP Morgan analyst Matthew Boss downgrades Five Below (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) from Neutral to Underweight and raises the price target from $89 to $95.

FIVE

JP Morgan Downgrades Five Below to Underweight, Raises Price Target to $95

INAQ's Special Meeting of Stockholders to Approve the Business Combination Scheduled to be Held on October 14, 2024
CORNELIUS, N.C. and NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Alpha Modus Corp. ("Alpha Modus"), a technology company with a core focus on artificial intelligence in retail, and Insight Acquisition Corp. ("Insight") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAQ#NASDAQ">INAQ</a>), a publicly traded special purpose acquisition company, announced today that the U.S. Securities and Exchange Commission ("SEC") has declared effective the registration statement on Form S-4 (as amended, the "Registration Statement") filed with the SEC related to the previously announced business combination (the "Business Combination"). Insight has also filed with the SEC the definitive proxy statement for its special meeting of stockholders (the "Special Meeting"), to, among other things, approve the Business Combination. &nbsp;
Upon closing of the Business Combination, which is subject to stockholder approval, the combined company will operate as "Alpha Modus Holdings, Inc." and its common stock and warrants are expected to commence trading on the Nasdaq Global Market ("Nasdaq") under the tickers "AMOD" and "AMODW", respectively, shortly thereafter.
For additional details regarding the Business Combination, please see the sources described below under, "Important Information About the Proposed Business Combination and Where to Find It".

INAQ

Alpha Modus And Insight Acquisition Corp. Announce Effectiveness Of Form S-4 Registration Statement For Proposed Business Combination,  Expects To Commence Trading On The Nasdaq Global Market Under The Tickers "AMOD"

Leerink Partners analyst Mani Foroohar reiterates 4D Molecular Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>) with a Outperform and lowers the price target from $40 to $36.

Leerink Partners Reiterates Outperform on 4D Molecular Therapeutics, Lowers Price Target to $36

RBC Capital analyst Luca Issi reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Outperform and maintains $300 price target.

ALNY

RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $300 Price Target

(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENB#NASDAQ">RENB</a>) PersonalAIze and RenovaroCube are proud to announce a strategic partnership to develop, validate, and commercialize&nbsp;Cube's&nbsp;AI-driven, multi-omic&nbsp;platform for&nbsp;early detection of cancer and other diseases. This strategic partnership aims to provide services to many AI companies and healthcare systems while also creating the next generation of medical diagnostics through cutting-edge AI by driving greater accuracy, transparency, and trust in healthcare solutions.

RENB

PersonalAIze And RenovaroCube Announce A Strategic Partnership To Develop, Validate, And Commercialize Cube's AI-Driven Platform For Early Detection Of Cancer And Other Diseases

TNDM

Tandem's t:slim X2 Insulin Pump Now Compatible With Lyumjev Ultra-Rapid Acting Insulin In The European Union

Jewett-Cameron Trading Company Ltd. ("Jewett-Cameron") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JCTCF#NASDAQ">JCTCF</a>), a company committed to innovative products that enrich outdoor spaces, today announced it has retained one of the industry's leading investor relations firms, Lytham Partners, LLC, to lead a strategic investor relations and shareholder communication program. &nbsp;
For more than 20 years, Lytham Partners has cultivated a highly diverse network of institutional investors, while creating a framework of best practices in all aspects of corporate and shareholder communications. In addition to their relationships with many of the most respected institutional investors, Lytham Partners has spent the past two decades creating an integrated platform enabling far-reaching exposure to investors in a consistent and in-depth format including the Lytham Partners Investor Conference Series. This platform includes a communications and positioning approach that is achieved through various means, including via press releases, conference calls, investor presentations, profiles, corporate access, and websites.

JCTCF

Jewett-Cameron Announces It Has Retained An Investor Relations Firms, Lytham Partners, LLC, To Lead A Strategic Investor Relations And Shareholder Communication Program

RealVision&#8217;s chief crypto analyst Jamie Coutts shared his insights on the current crypto market downturn, hinting at a potential bullish shift based <a href="https://www.benzinga.com/money/what-you-need-to-know-about-technical-analysis">on technical indicators</a>.
What Happened: In a detailed <a href="https://x.com/Jamie1Coutts/status/1836192082127655274">thread</a> of X, Coutts highlighted a 55% pullback of the top 200 cryptocurrencies equally weighed over the past six months. 
He noted that despite the downtrend, the risk/reward ratio is favorable for adding to select assets at these levels. Coutts also pointed out a sharp move higher on the altseason indicator, suggesting a potential end to the bearish thrust.
He further explained that a return to a bullish regime could be indicated when more than 45% of assets trade above their 200-day moving average. Currently, only 11% of assets are above this mark.
Coutts believes that traders will need the price to break out of downtrends, but for allocators, current price levels are desirable to add as the risk/reward is favorable.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40926060/bitcoin-is-in-for-a-massive-bull-run-if-this-2020-pattern-repeats-analyst-says">Bitcoin Is In For A &#8216;Massive Bull Run&#8217; If This 2020 Pattern Repeats, Analyst Says</a>
Why It Matters: Coutts' analysis contrasts the last months of persistent sideways trading. The analyst sees early signs of a potential reversal, similar to that in Q3 2023.
He also emphasized the role of liquidity in driving the market, stating that it has now turned decisively bullish and is <a href="https://x.com/Jamie1Coutts/status/1824053788027851175">likely</a> to push Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) higher. 
Despite the price decline over the past six months, key crypto ecosystem fundamental metrics have performed well, with addresses up by 73% and rising transactions.
While acknowledging the current bearish price action, Coutts suggested that the final throes of the big flush of the past months could make Q4 critical for 12-month forward returns for allocators.
What&#8217;s Next: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40919168/ethereum-co-founder-says-donald-trump-is-certainly-the-favorite-over-kamala-harris-for-cry">Ethereum Co-Founder Says Donald Trump Is &#8216;Certainly The Favorite&#8217; Over Kamala Harris For Crypto</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

Raoul Pal's Chief Crypto Analyst Says The Bull Market Is Back When This Indicator Hits 45% (It's Now At 11%)

Iconic Golf Simulator Company Awards Local Entrepreneurs&nbsp;Opportunity to Develop 80 New Centers
CHICAGO, Sept. 19, 2024 /PRNewswire/ -- TruGolf Links Franchising, LLC ("TruGolf"), owned by TruGolf Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUG#NASDAQ">TRUG</a>), a leading provider of golf simulator software and hardware, announced today the signing of its second regional development deal. Led by experienced entrepreneurs Bob Early and Ron&nbsp;Rzansa, the deal spans the surrounding Chicago suburbs and into the northwest region of Indiana. The agreement includes the rights to open 80 locations, either owned or franchised, with plans to hit the markets aggressively and create close ties within local communities across the region.

TRUG

TruGolf Links Announces The Signing Of Its Second Regional Development Deal, Includes The Rights To Open 80 Locations, Either Owned Or Franchised, With Plans To Hit The Markets Aggressively And Create Close Ties Within Local Communities Across The Region

Leerink Partners analyst Joseph Schwartz maintains Applied Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>) with a Outperform and raises the price target from $11 to $14.

APLT

Leerink Partners Maintains Outperform on Applied Therapeutics, Raises Price Target to $14

Jefferies analyst Julien Dumoulin-Smith initiates coverage on NextEra Energy Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEP#NYSE">NEP</a>) with a Buy rating and announces Price Target of $28.

Initiation

Jefferies Initiates Coverage On NextEra Energy Partners with Buy Rating, Announces Price Target of $28

Acurx Pharmaceuticals GAAP EPS of -$0.28 misses by $0.04

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Acurx Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/acxp-stock-quote/">ACXP</a>) just reported results for the first quarter of 2024.<ul><li>Acurx Pharmaceuticals reported earnings per share of -28 cents. This was below the analyst estimate for EPS of -24 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/acxp-stock-earnings-acurx-pharmaceuticals-for-q1-of-2024/">ACXP Stock Earnings: Acurx Pharmaceuticals Misses EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ACXP Stock Earnings: Acurx Pharmaceuticals Misses EPS for Q1 2024

Acurx Pharmaceuticals, Inc. (ACXP) Q1 2024 Earnings Call Transcript

Ed Arce, an analyst from H.C. Wainwright, maintained the Buy rating on Acurx Pharmaceuticals (ACXP – Research Report). The associated price target ...

Buy Rating Affirmed for Acurx Pharmaceuticals Amid Promising CDI Drug Candidate Progress and Solid Financials

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Acurx Pharmaceuticals (ACXP – Research Report), with a p...

Maxim Group Sticks to Its Buy Rating for Acurx Pharmaceuticals (ACXP)

Acurx Pharmaceuticals GAAP EPS of -$0.26 misses by $0.04

Acurx Pharmaceuticals, Inc. (ACXP) Q2 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Acurx Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/acxp-stock-quote/">ACXP</a>) just reported results for the second quarter of 2024.<ul><li>Acurx Pharmaceuticals reported earnings per share of -26 cents. This was below the analyst estimate for EPS of -22 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/acxp-stock-earnings-acurx-pharmaceuticals-for-q2-of-2024/">ACXP Stock Earnings: Acurx Pharmaceuticals Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ACXP Stock Earnings: Acurx Pharmaceuticals Misses EPS for Q2 2024

Ibezapolstat's Strategic Advancements and Market Potential Bolster Buy Rating for Acurx Pharmaceuticals

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Acurx Pharmaceuticals (ACXP – Research Report), with a price ta...

Acurx Pharmaceuticals' Ibezapolstat: A Strong Buy Ahead of Phase 3 for CDI Treatment

Press Releases

Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection

New to The Street Announces Episode 576, Four Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Tonight, Thursday, June 6, 2024, at 9:30 PM PT

Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference

Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update

USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome

Earnings

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update

New to The Street TV Announces Episode 583, Five Riveting Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Saturday, August 10, 2024, at 6:30 PM ET

New to The Street Announces Episode 590, Five Corporate Interviews, Airing on the Fox Business Network, Tonight Monday, August 19, 2024, at 10:30 PM PT

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Acurx Pharmaceuticals

Acurx Pharmaceuticals (ACXP) Forecast

Acurx Pharmaceuticals (NASDAQ:ACXP) Stock, Quote.Headers.trade-ideas